Title: 4 HOUSE BILL 2801 By: Marti of the House
Official Title: 4 HOUSE BILL 2801 By: Marti of the House
Number of Sections: 1
Source: versions - Floor (House)
Media Type: application/pdf
Strikethrough Detection: 4 sections found

================================================================================

Section 1:
1 HOUSE OF REPRESENTATIVES - FLOOR VERSION
2 STATE OF OKLAHOMA
3 1st Session of the 60th Legislature (2025)
5 and
6 Stanley of the Senate
7
8
9 AS INTRODUCED
10 An Act relating to antipsychotic drugs; amending 56
O.S. 2021, Section 204, which relates to vendor drug
11 program; authorizing the Oklahoma Health Care
Authority to approve prior authorized antipsychotics;
12 providing for certain disorders; establishing certain
prior authorization; and providing an effective date.
13
14
15
16 BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA:
17 SECTION 1. AMENDATORY 56 O.S. 2021, Section 204, is
18 amended to read as follows:
19 Section 204. A. Except as otherwise provided, the Oklahoma
20 Health Care Authority shall be authorized and directed to establish
21 a vendor drug program to provide any drugs that have been approved
22 and designated as safe and effective by the federal Food and Drug
23 Administration, and that are prescribed by a licensed medical,
24 dental, podiatric, or osteopathic practitioner for eligible
HB2801 HFLR Page 1
BOLD FACE denotes Committee Amendments.
1 reci pients of assistance payments suffering from painful or life-
2 endangering diseases or other persons who are suffering from a
3 catastrophic illness.
4 B. The Authority shall, in accordance with federal law, not be
5 obligated to cover any outpatient drugs of a manufacturer which has
6 not entered into or which does not have in effect a rebate agreement
7 with the Secretary of Health and Human Services on behalf of the
8 state.
9 C. Such program shall, to the fullest extent possible, be
10 established and maintained in conjunction with existing federal
11 programs of prescribed drugs so as to earn the maximum of federal
12 financial participation. Exempt from the provisions of this section
13 are the following drugs or classes of drugs, or their medical uses:
14 1. Agents when used for anorexia or weight gain;
15 2. Agents when used to promote fertility;
16 3. Agents when used for cosmetic purposes or hair growth;
17 4. Agents when used for the symptomatic relief of coughs and
18 colds;
19 5. Agents when used to promote smoking cessation;
20 6. Prescription vitamins and mineral products, except prenatal
21 vitamins and fluoride preparations;
22 7. Nonprescription drugs;
23 8. Covered outpatient drugs when the manufacturer seeks to
24 require as a condition of sale that associated tests or monitoring
HB2801 HFLR Page 2
BOLD FACE denotes Committee Amendments.
1 serv ices be purchased exclusively from the manufacturer or its
2 designee;
3 9. Drugs described in paragraph 3 of subsection c of Section
4 107 of the Drug Amendments of 1962, 21 U.S.C., Section 107(c)(3),
5 and identical, similar or related drugs, within the meaning of
6 paragraph 1 of subsection b of Section 310.6 of Title 21 of the Code
7 of Federal Regulations;
8 10. Barbiturates; or
9 11. Benzodiazepines;
10 provided, however, the Authority shall be authorized to include
11 specific drugs within these categories for reimbursement based upon
12 specific medical need.
13 D. The Authority shall be authorized to establish a prospective
14 drug utilization review program for the H2 Antagonists; provided
15 that such limitations are in compliance with federal Food and Drug
16 Administration Agency-approved product labeling.
17 E. The Authority shall approve a prior authorization request
18 for any FDA approved atypical antipsychotic that is not on the
19 preferred drug list for the treatment and prevention of mood
20 disorders with psychotic symptoms including bipolar disorders,
21 schizophrenia, and schizotypal or delusion disorders. Medications
22 included under this section shall be available at parity to other
23 branded medications in the same class. Approval shall be based on
24
HB2801 HFLR Page 3
BOLD FACE denotes Committee Amendments.
1 pati ent's claims history or health care provider attestation of one
2 of the following conditions for the Medicaid client:
3 1. A trial and failure of any preferred atypical antipsychotic
4 in the preceding three hundred sixty-five (365) days; or
5 2. The patient is stable on an atypical antipsychotic that is
6 not included on the preferred drug list.
7 SECTION 2. This act shall become effective November 1, 2025.
8
9 COMMITTEE REPORT BY: COMMITTEE ON HEALTH AND HUMAN SERVICES
OVERSIGHT, dated 02/26/2025 – DO PASS.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
HB2801 HFLR Page 4
BOLD FACE denotes Committee Amendments.
[DELETED:  P B   a S]
[DELETED:  P]
[DELETED:  P]
[DELETED:  P]


================================================================================

Raw Text:
1 HOUSE OF REPRESENTATIVES - FLOOR VERSION
2 STATE OF OKLAHOMA
3 1st Session of the 60th Legislature (2025)
4 HOUSE BILL 2801 By: Marti of the House
5 and
6 Stanley of the Senate
7
8
9 AS INTRODUCED
10 An Act relating to antipsychotic drugs; amending 56
O.S. 2021, Section 204, which relates to vendor drug
11 program; authorizing the Oklahoma Health Care
Authority to approve prior authorized antipsychotics;
12 providing for certain disorders; establishing certain
prior authorization; and providing an effective date.
13
14
15
16 BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA:
17 SECTION 1. AMENDATORY 56 O.S. 2021, Section 204, is
18 amended to read as follows:
19 Section 204. A. Except as otherwise provided, the Oklahoma
20 Health Care Authority shall be authorized and directed to establish
21 a vendor drug program to provide any drugs that have been approved
22 and designated as safe and effective by the federal Food and Drug
23 Administration, and that are prescribed by a licensed medical,
24 dental, podiatric, or osteopathic practitioner for eligible
HB2801 HFLR Page 1
BOLD FACE denotes Committee Amendments.

1 reci pients of assistance payments suffering from painful or life-
2 endangering diseases or other persons who are suffering from a
3 catastrophic illness.
4 B. The Authority shall, in accordance with federal law, not be
5 obligated to cover any outpatient drugs of a manufacturer which has
6 not entered into or which does not have in effect a rebate agreement
7 with the Secretary of Health and Human Services on behalf of the
8 state.
9 C. Such program shall, to the fullest extent possible, be
10 established and maintained in conjunction with existing federal
11 programs of prescribed drugs so as to earn the maximum of federal
12 financial participation. Exempt from the provisions of this section
13 are the following drugs or classes of drugs, or their medical uses:
14 1. Agents when used for anorexia or weight gain;
15 2. Agents when used to promote fertility;
16 3. Agents when used for cosmetic purposes or hair growth;
17 4. Agents when used for the symptomatic relief of coughs and
18 colds;
19 5. Agents when used to promote smoking cessation;
20 6. Prescription vitamins and mineral products, except prenatal
21 vitamins and fluoride preparations;
22 7. Nonprescription drugs;
23 8. Covered outpatient drugs when the manufacturer seeks to
24 require as a condition of sale that associated tests or monitoring
HB2801 HFLR Page 2
BOLD FACE denotes Committee Amendments.

1 serv ices be purchased exclusively from the manufacturer or its
2 designee;
3 9. Drugs described in paragraph 3 of subsection c of Section
4 107 of the Drug Amendments of 1962, 21 U.S.C., Section 107(c)(3),
5 and identical, similar or related drugs, within the meaning of
6 paragraph 1 of subsection b of Section 310.6 of Title 21 of the Code
7 of Federal Regulations;
8 10. Barbiturates; or
9 11. Benzodiazepines;
10 provided, however, the Authority shall be authorized to include
11 specific drugs within these categories for reimbursement based upon
12 specific medical need.
13 D. The Authority shall be authorized to establish a prospective
14 drug utilization review program for the H2 Antagonists; provided
15 that such limitations are in compliance with federal Food and Drug
16 Administration Agency-approved product labeling.
17 E. The Authority shall approve a prior authorization request
18 for any FDA approved atypical antipsychotic that is not on the
19 preferred drug list for the treatment and prevention of mood
20 disorders with psychotic symptoms including bipolar disorders,
21 schizophrenia, and schizotypal or delusion disorders. Medications
22 included under this section shall be available at parity to other
23 branded medications in the same class. Approval shall be based on
24
HB2801 HFLR Page 3
BOLD FACE denotes Committee Amendments.

1 pati ent's claims history or health care provider attestation of one
2 of the following conditions for the Medicaid client:
3 1. A trial and failure of any preferred atypical antipsychotic
4 in the preceding three hundred sixty-five (365) days; or
5 2. The patient is stable on an atypical antipsychotic that is
6 not included on the preferred drug list.
7 SECTION 2. This act shall become effective November 1, 2025.
8
9 COMMITTEE REPORT BY: COMMITTEE ON HEALTH AND HUMAN SERVICES
OVERSIGHT, dated 02/26/2025 – DO PASS.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
HB2801 HFLR Page 4
BOLD FACE denotes Committee Amendments.

[DELETED:  P B   a S]
[DELETED:  P]
[DELETED:  P]
[DELETED:  P]